Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 327-336

  Bramuglia, Guillermo F ^a   Cortada, Catalina M ^a   Curras, Verónica ^a   Höcht, Christian ^a   Buontempo, Fabián ^b   Mato, Gabriel ^b   Niselman, Viviana ^a   Rubio, Modesto ^a,c   Carballo, Marta ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c Instituto de Investigaciones Farmacologicas   (Argentina)

Author keywords

ABC transporters; Bioavailability; Indinavir; Oral absorption; P glycoprotein; Pharmaco kinetics

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; INDINAVIR; RHODAMINE 123;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; NONLINEAR REGRESSION ANALYSIS; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEADY STATE; ULTRAVIOLET RADIATION; VENOUS BLOOD;

EID: 58149215822     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21411     Document Type: Article

References (43)

1. Davidson AL. 2002. Mechanism of coupling of transport to hydrolysis in bacterial ATP-binding cassette transporters. J Bacteriol 184:1225-1233.
2. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the niultidrug transporter. Annu Rev Biochem 62:385-427.
3. Higgins CF, Linton KJ. 2004. The ATP switch model for ABC transporters. Nat Struct Mol Biol 11:918-926.
4. Senior AE, Al-Shawi MK, Urbatsch IL. 1995. The catalytic cycle of P-glycoprotein. FEBS Lett 377: 285-289.
5. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharin Res 15:1160-1167.
6. Cordon-Cardo C, O'Brien JP, Boccia J, Casas D, Bertino JR, Melamed MR. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissue. J Histochem Cytochem 8:1277-1287.
7. Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham MC. 1989. Immunohisto-chemieal localization in normal tissue of different epitopes in the multidrug transport protein p170: Evidence for localization in brain capillaries and crossreactivity of one antibody with muscle protein. J Histochem Cytochem 7:159-164.
8. Herbert MF. 1997. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclos-porine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 7:201-214.
9. Arimori K, Nakano M. 1998. Drug exsorption from blood into the gastrointestinal tract. Pharm Res 5:371-376.
10. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon K, Sehmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
11. Chana LMS, Lowesa S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51.
12. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. 2000. Influence of P-glycoprotein on the transport and metabolismof indinavir in Caco-2 cells expressing cytochrome P-450 3 A4. J Pharmacol Exp Ther 292:310-318.
13. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF. 2000. The disposition of saquinavir in normal and p-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28:1058-1062.
14. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
15. Van Asperen J, Van Tellingen O, Beijnen J. 2000. The role of mdrl a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 8:264-267.
16. Troutman M, Thakker D. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20: 1200-1209.
17. Saitoh H, Hatakeyama M, Eguchi O, Oda M, Takada M. 1998. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci 87:73-75.
18. Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin JL, de Cremoux P, Delvincourt C, Demur C, Drenou B, Fenneteau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse MC, Gosselin P, Jouault H, Lacave R, Eobert J. 1997. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 11:1086-1094.
19. Hoffmeyer S, Burk O, von Riehter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multi-drug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
20. Pace L, Catalano L, Del Vecchio S, De Renzo A, Fonti R, Salvatore B, Andretta C, Di Nuzzo C, Rotoli B, Salvatore M. 2005. Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J Nucl Med Mol Imaging 49:281-285.
21. Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR. 2006. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol 24:4225-4227.
22. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. 1996. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumor: Consensus recommendations. Cancer Res 56:3010-3020.
23. Aarnoutse RE, Wasmuth JC, Fatkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hek-ster YA, Burger DM, Rockstroh JK. 2003. Administration of indinavir and low-dose ritonavir (800/ 100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antivir Ther 8: 309-314.
24. Boyum A. 1964. Separation of white blood cells. Nature 204:793-794.
25. Chaudhary PM, Mechetner EB, Roninson IB. 1991. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735-2739.
26. Di Cenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD, The Adult AIDS Clinical Trials Group Protocol 368/886. 2003. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 47:1929-1935.
27. Zhou XJ, Havlir DV, Richman DD, Acosta EP, Hirsch M, Collier AC, Tebas P, Sonimadossi JP. 2000. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 14:2869-2876.
28. Csajka C, Marzolini C, Fattinger K, Deeosterd LA, Telenti A, Biollaz J, Buclin T. 2004. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 48:3226-3232.
29. Benet LZ, Cummins CL. 2001. The drug efflux-metabolism alliance: Biochemical aspects. Adv Drug Deliv Rev 50:S3-S11.
30. Benet LZ, Cummins CL, Wu CY. 2003. Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393-398.
31. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Ver-nazza P, Eap CB, Telenti A, for the Swiss HIV Cohort Study. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359:30-36.
32. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. 2005. An MDR 1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19:371-380.
33. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini C, Esposito R, Cossarizza A. 2003. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696-1698.
34. Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, Poizot-Martin I.2007. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the. pharmacokinetics of indinavir in HlV-infected patients. Br J Clin Pharmacol 64:353-362.
35. Bramuglia GF, Curras V, Hocht C, Mangano A, Niselman V, Cáceres Guido P, Mecikovsky D, Bel-lusci C, Bologna R, Sen L, Rubio MC. 2007. Therapeutic drug monitoring of indinavir and lopinavir boosted with ritonavir in children with HIV-1 infection: Possible influence of P-gp on protease inhibitors absorption. Ther Drug Monit 29:487.
36. Blokzijl H, Vander Borght S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Ros-kams TA, Moshage H, Jansen PL, Faber KN. 2007. Decreased P-glycoprotein (P-gp/MDRl) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 13:710-720.
37. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. 2000. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118:279-288.
38. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. 2005. Expression of the drug transporters MDR1/ ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 70:949-958.
39. Cortada CM, Escobar A, Curras M, Bramuglia G, Carballo MA, Niselman AV, Rubio MC. 2007. Analysis of lymphocitic P-gp activity. Biocell 31:88.
40. Langmann P, Zilly M, Weissbrich B, Desch S, Väth T, Klinker H. 2002. Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection 30:13-16.
41. Collin F, Chêne G, Retout S, Peytavin G, Salmon D, Bouvet E, Raffi F, Garraffo R, Mentré F, Duval X, ANRS CO8 Aproco-Copilote Study Group. 2007. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther Drug Monit 29:164-170.
42. Veau C, Faivre L, Tardivel S, Soursac M, Banide H, Lacour B, Farinotti R. 2002 Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 302:742-750.
43. Lee G, Piquette-Miller M. 2003. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J Pharm Sci 92:2152-2163.